Home paracentesis for cancer-related malignant ascites

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the use of at-home ultrasound-guided paracentesis for adults with cancer-related malignant ascites who have already had a clinic-based procedure. Participants will receive an at-home procedure to remove ascitic fluid and will be monitored for symptom changes. The goal is to determine if home-based paracentesis can improve comfort and quality of life while ensuring safety. Eligibility includes adults with active ascites symptoms, confirmed cancer, ability to consent, and suitability for home-based ultrasound-guided drainage. Exclusion criteria include rapidly deteriorating condition, major abdominal wall issues, or need for concurrent procedures that require hospitalization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants aged ≥ 18 years
* Able to speak and understand English.
* Has completed an initial clinic-based paracentesis procedure.
* Confirmed diagnosis of cancer.
* Symptoms related to ascites requiring procedure in the opinion of the investigator.
* Eligible to receive an ultrasound-guided paracentesis procedure at home in the opinion of the investigator.
* If applicable, participant is able to safely hold anticoagulant therapy per institutional standards prior to the procedure in the opinion of the investigator.
* For participants of child-bearing potential, participant is following standard of care guidelines for contraception.
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

* Rapidly deteriorating condition or suspected bowel obstruction.
* Large ventral hernias or prior complications from paracentesis.
* Need for concurrent procedures requiring hospital resources.
* Known lack of safe environment or inability to obtain sterile conditions at home.
* Any condition that would, in the Investigator's judgment, contraindicate the participant's participation in the procedure or clinical study due to safety concerns or compliance with clinical study procedures. For example,
* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.

Where it's running

• Huntsman Cancer Institute at the University of Utah
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Anna Beck, MD — Huntsman Cancer Institute
• Study coordinator: Susan Sharry
• Email: susan.sharry@hci.utah.edu
• Phone: 801-585-3453

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TLR9-based immunotherapy for peritoneal cancer with ascites

  This trial tests ACM-CpG injections into the abdomen to see if it’s safe and can help people with peritoneal metastases or malignant ascites from colorectal or appendiceal cancer.

  Recruiting Phase 1 Brown University · Providence, Rhode Island · NCT07658196

• Intraperitoneal liposomal irinotecan alone or with rmhTNF or bevacizumab for malignant ascites after prior treatments

  This will try an injected form of liposomal irinotecan, alone or with rmhTNF or bevacizumab, in adults with malignant ascites who have not responded to standard therapies.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07397819

• SIM0388 intraperitoneal treatment for malignant ascites

  This Phase I trial will test whether intraperitoneal Docetaxel polymeric micelles (SIM0388) can safely reduce malignant ascites in adults with advanced solid tumors who have exhausted or are not candidates for standard therapies.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07007988

• Combining Bevacizumab and Serplulimab with a New Treatment for Malignant Ascites

  This study is testing a new treatment that combines two drugs with a special therapy to see if it can help people with severe abdominal fluid buildup from digestive system cancers who haven't found relief from other treatments.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT06433869

• Infusing tocilizumab into chest and abdominal cavities for advanced cancer patients

  This study is testing if giving tocilizumab directly into the chest and abdomen can help advanced cancer patients with fluid buildup feel better and respond to treatment.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT06016179

• Dual-targeting CAR-T therapy for advanced cancer patients with pleural or peritoneal metastases

  This study is testing a new type of CAR-T therapy that targets specific proteins in advanced cancer patients with tumors in the pleural or peritoneal cavities to see if it helps them when other treatments haven't worked.

  Recruiting Phase 1 Sichuan University · Chengdu, Sichuan · NCT05477927

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.